Therapeutic ultrasound contrast agents for the enhancement of tumor diagnosis and tumor therapy

Hyungwon Moon, Changhan Yoon, Tae Woong Lee, Kyoung Su Ha, Jin Ho Chang, Tai Kyong Song, Kwang Meyung Kim, Hyuncheol Kim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The functionality of ultrasound in early cancer detection is limited because of its relatively low contrast resolution. Because it has a high degree of echogenicity, a microbubble contrast agent is often used to overcome this intrinsic limitation of imaging at low-contrast resolution. A targeted and drug-loaded microbubble contrast agent for simultaneous diagnosis and therapy has recently been investigated. However, no optimized theragnosis ultrasoundmicrobubbles have been developed. Paclitaxel (PTX)-encapsulating human serum albumin nanoparticles (PTX-HSA-NPs) were conjugated onto an ultrasound microbubbles (PTX-HSA-NPs-MBs) fabricated in the laboratory to result in a narrow size distribution (1-7± 0-7 μm) and an optimal resonance frequency of 3 MHz. After intravenous injection of HSA-NPs-MBs, echogenicity in the tumor xenografted with breast cancer MCF-7 cells was significantly enhanced, showing the possibility of early cancer diagnosis. Mice injected with PTX-HSA-NPs-MBs showed higher survival rates in comparison with control groups, demonstrating the possibility of theragnosis. In the present study, the conjugation of PTX-HSA-NPs onto the ultrasound microbubbles simultaneously provided (1) enhanced ultrasound signal generation, (2) sufficient drug-loading capacity, (3) ability to deliver drugs to a preferred tumor site, and (4) increased stability in blood circulation.

Original languageEnglish
Pages (from-to)1183-1192
Number of pages10
JournalJournal of Biomedical Nanotechnology
Volume11
Issue number7
DOIs
Publication statusPublished - 2015 Jul 1
Externally publishedYes

Fingerprint

Microbubbles
Paclitaxel
Contrast Media
Tumors
Ultrasonics
Early Detection of Cancer
Neoplasms
Pharmaceutical Preparations
Blood Circulation
MCF-7 Cells
Hemodynamics
Therapeutics
Serum Albumin
Intravenous Injections
Nanoparticles
Breast Neoplasms
Imaging techniques
Control Groups

Keywords

  • Drug delivery
  • Human serum albumin
  • Microbubble
  • Theragnosis
  • Tumor
  • Ultrasound contrast agent
  • Ultrasound imaging

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this

Moon, H., Yoon, C., Lee, T. W., Ha, K. S., Chang, J. H., Song, T. K., ... Kim, H. (2015). Therapeutic ultrasound contrast agents for the enhancement of tumor diagnosis and tumor therapy. Journal of Biomedical Nanotechnology, 11(7), 1183-1192. https://doi.org/10.1166/jbn.2015.2056

Therapeutic ultrasound contrast agents for the enhancement of tumor diagnosis and tumor therapy. / Moon, Hyungwon; Yoon, Changhan; Lee, Tae Woong; Ha, Kyoung Su; Chang, Jin Ho; Song, Tai Kyong; Kim, Kwang Meyung; Kim, Hyuncheol.

In: Journal of Biomedical Nanotechnology, Vol. 11, No. 7, 01.07.2015, p. 1183-1192.

Research output: Contribution to journalArticle

Moon, Hyungwon ; Yoon, Changhan ; Lee, Tae Woong ; Ha, Kyoung Su ; Chang, Jin Ho ; Song, Tai Kyong ; Kim, Kwang Meyung ; Kim, Hyuncheol. / Therapeutic ultrasound contrast agents for the enhancement of tumor diagnosis and tumor therapy. In: Journal of Biomedical Nanotechnology. 2015 ; Vol. 11, No. 7. pp. 1183-1192.
@article{0600be206efa48b0ad1ecfd8d62bc8dd,
title = "Therapeutic ultrasound contrast agents for the enhancement of tumor diagnosis and tumor therapy",
abstract = "The functionality of ultrasound in early cancer detection is limited because of its relatively low contrast resolution. Because it has a high degree of echogenicity, a microbubble contrast agent is often used to overcome this intrinsic limitation of imaging at low-contrast resolution. A targeted and drug-loaded microbubble contrast agent for simultaneous diagnosis and therapy has recently been investigated. However, no optimized theragnosis ultrasoundmicrobubbles have been developed. Paclitaxel (PTX)-encapsulating human serum albumin nanoparticles (PTX-HSA-NPs) were conjugated onto an ultrasound microbubbles (PTX-HSA-NPs-MBs) fabricated in the laboratory to result in a narrow size distribution (1-7± 0-7 μm) and an optimal resonance frequency of 3 MHz. After intravenous injection of HSA-NPs-MBs, echogenicity in the tumor xenografted with breast cancer MCF-7 cells was significantly enhanced, showing the possibility of early cancer diagnosis. Mice injected with PTX-HSA-NPs-MBs showed higher survival rates in comparison with control groups, demonstrating the possibility of theragnosis. In the present study, the conjugation of PTX-HSA-NPs onto the ultrasound microbubbles simultaneously provided (1) enhanced ultrasound signal generation, (2) sufficient drug-loading capacity, (3) ability to deliver drugs to a preferred tumor site, and (4) increased stability in blood circulation.",
keywords = "Drug delivery, Human serum albumin, Microbubble, Theragnosis, Tumor, Ultrasound contrast agent, Ultrasound imaging",
author = "Hyungwon Moon and Changhan Yoon and Lee, {Tae Woong} and Ha, {Kyoung Su} and Chang, {Jin Ho} and Song, {Tai Kyong} and Kim, {Kwang Meyung} and Hyuncheol Kim",
year = "2015",
month = "7",
day = "1",
doi = "10.1166/jbn.2015.2056",
language = "English",
volume = "11",
pages = "1183--1192",
journal = "Journal of Biomedical Nanotechnology",
issn = "1550-7033",
publisher = "American Scientific Publishers",
number = "7",

}

TY - JOUR

T1 - Therapeutic ultrasound contrast agents for the enhancement of tumor diagnosis and tumor therapy

AU - Moon, Hyungwon

AU - Yoon, Changhan

AU - Lee, Tae Woong

AU - Ha, Kyoung Su

AU - Chang, Jin Ho

AU - Song, Tai Kyong

AU - Kim, Kwang Meyung

AU - Kim, Hyuncheol

PY - 2015/7/1

Y1 - 2015/7/1

N2 - The functionality of ultrasound in early cancer detection is limited because of its relatively low contrast resolution. Because it has a high degree of echogenicity, a microbubble contrast agent is often used to overcome this intrinsic limitation of imaging at low-contrast resolution. A targeted and drug-loaded microbubble contrast agent for simultaneous diagnosis and therapy has recently been investigated. However, no optimized theragnosis ultrasoundmicrobubbles have been developed. Paclitaxel (PTX)-encapsulating human serum albumin nanoparticles (PTX-HSA-NPs) were conjugated onto an ultrasound microbubbles (PTX-HSA-NPs-MBs) fabricated in the laboratory to result in a narrow size distribution (1-7± 0-7 μm) and an optimal resonance frequency of 3 MHz. After intravenous injection of HSA-NPs-MBs, echogenicity in the tumor xenografted with breast cancer MCF-7 cells was significantly enhanced, showing the possibility of early cancer diagnosis. Mice injected with PTX-HSA-NPs-MBs showed higher survival rates in comparison with control groups, demonstrating the possibility of theragnosis. In the present study, the conjugation of PTX-HSA-NPs onto the ultrasound microbubbles simultaneously provided (1) enhanced ultrasound signal generation, (2) sufficient drug-loading capacity, (3) ability to deliver drugs to a preferred tumor site, and (4) increased stability in blood circulation.

AB - The functionality of ultrasound in early cancer detection is limited because of its relatively low contrast resolution. Because it has a high degree of echogenicity, a microbubble contrast agent is often used to overcome this intrinsic limitation of imaging at low-contrast resolution. A targeted and drug-loaded microbubble contrast agent for simultaneous diagnosis and therapy has recently been investigated. However, no optimized theragnosis ultrasoundmicrobubbles have been developed. Paclitaxel (PTX)-encapsulating human serum albumin nanoparticles (PTX-HSA-NPs) were conjugated onto an ultrasound microbubbles (PTX-HSA-NPs-MBs) fabricated in the laboratory to result in a narrow size distribution (1-7± 0-7 μm) and an optimal resonance frequency of 3 MHz. After intravenous injection of HSA-NPs-MBs, echogenicity in the tumor xenografted with breast cancer MCF-7 cells was significantly enhanced, showing the possibility of early cancer diagnosis. Mice injected with PTX-HSA-NPs-MBs showed higher survival rates in comparison with control groups, demonstrating the possibility of theragnosis. In the present study, the conjugation of PTX-HSA-NPs onto the ultrasound microbubbles simultaneously provided (1) enhanced ultrasound signal generation, (2) sufficient drug-loading capacity, (3) ability to deliver drugs to a preferred tumor site, and (4) increased stability in blood circulation.

KW - Drug delivery

KW - Human serum albumin

KW - Microbubble

KW - Theragnosis

KW - Tumor

KW - Ultrasound contrast agent

KW - Ultrasound imaging

UR - http://www.scopus.com/inward/record.url?scp=84918549572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918549572&partnerID=8YFLogxK

U2 - 10.1166/jbn.2015.2056

DO - 10.1166/jbn.2015.2056

M3 - Article

C2 - 26307841

AN - SCOPUS:84918549572

VL - 11

SP - 1183

EP - 1192

JO - Journal of Biomedical Nanotechnology

JF - Journal of Biomedical Nanotechnology

SN - 1550-7033

IS - 7

ER -